NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships
January 10 2022 - 9:00AM
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has
appointed Brandi Damkier as Vice President, Clinical Partnerships.
Ms. Damkier will be responsible for expanding the Company's
DPNCheck® clinical partnerships and advancing the Company's
footprint in the value-based healthcare market. DPNCheck is a
widely used point-of-care test that provides physicians with fast,
accurate and cost-effective screening, diagnosis and monitoring of
peripheral neuropathies. It is often used to stage the severity of
Diabetic Peripheral Neuropathy (DPN), which is the most common
specific cause of peripheral nerve disease and a ubiquitous
long-term complication of diabetes that may progress to foot ulcers
and amputation.
Ms. Damkier brings to the company over 20 years of experience
working with health plans, value-based providers and healthcare
technology companies driving market strategy and revenue growth.
Ms. Damkier was most recently at eHealth, Inc., where she held the
position of Director, Value Based Provider Partnerships. In this
role, she was responsible for building partnerships with the
largest and most innovative Medicare at-risk provider networks and
Medicare Advantage health plans. Prior to that role, Ms. Damkier
was the Vice President, Business Development at CareCentrix Inc,
where she was responsible for building partnerships with Medicare
Advantage health plans for post-acute management services. Ms.
Damkier has also held senior business development roles at NTT
Data, Inc., Alliance Healthcare Services, Cardinal Health and
Allscripts, Inc. She holds a Bachelor of Arts Degree from
University of California San Diego.
"We are fortunate to have someone with Brandi's deep experience
and impressive record of success in value-based care markets and
healthcare technology join us to help build the DPNCheck business,”
said Shai N. Gozani M.D., Ph.D., NeuroMetrix Chief Executive
Officer. "This is an exciting and pivotal time for us as we look to
expand DPNCheck's footprint within Medicare Advantage and other
value-based care models. We are looking forward to having Brandi
help lead this effort."
About DPNCheck
DPNCheck is an automated, fast, accurate, and quantitative nerve
conduction test used to evaluate peripheral neuropathies. It
is designed to be used by clinicians at the point-of-care to
objectively detect, stage, and monitor peripheral
neuropathies. Please visit at www.dpncheck.com
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the
development and global commercialization of non-invasive medical
devices for the diagnosis and treatment of pain and neurological
disorders. The Company has three commercial products.
DPNCheck® is a diagnostic device that provides rapid,
point-of-care detection of peripheral neuropathies.
ADVANCE® is a diagnostic device that provides automated,
in-office nerve conduction studies for the evaluation of entrapment
neuropathies. Quell® is a wearable neurostimulation device
indicated for treatment of lower extremity chronic pain. For more
information, visit NeuroMetrix.com.
Source: NeuroMetrix, Inc.Thomas T. HigginsSVP and Chief
Financial
Officer781-314-2761neurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2023 to Apr 2024